RE
Replimune Group, Inc.
REPL · NASDAQ
$13.42 +2.91% (+$0.38)
1M +3.87%
Market Cap $1.10B
P/E Ratio -
Div. Yield -
ROE 159.33%
Bulios Fair Price
$12.61
6.0% downside
Current Price
$13.42
Undervalued Fair Value Overvalued
According to Bulios Fair Price, REPL is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
1/9Valuation
0 /100
Expensive P/B 10.37x
EV/EBITDA N/A
P/S N/A
Growth
0 /100
Declining Book val. growth 33.11%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 159.33%
ROA 117.65%
Asset turnover 0.00x
Debt
69 /100
Low Current ratio 5.23x
Int. coverage -30.82x
Debt/Equity 0.26x
Stability
78 /100
Stable EPS volatility 8.40%
Profitable years 0
Beta 0.94x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about REPL
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Sushil Patel
Employees
465
Headquarters
Woburn
Upcoming events
05 NOV
Earnings
Upcoming earnings report